Humira

Humira is a biologic approved for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, Crohn's disease, and rheumatoid arthritis.

What is Humira?

Humira (also know by its generic name adalimumab) is a TNF-alpha inhibitor biologic approved by the FDA in October 2005 for use in adult patients to treat active psoriatic arthritis and in January 2008 to treat moderate-to-severe psoriasis. It is also approved to treat rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and uveitis.

For adult patients with psoriatic arthritis, Humira is administered every other week. For adult patients with psoriasis, Humira is administered at week 0 and then every other week starting one week after initial dose. Humira is administered by injection under the skin.

To learn more, please visit the Humira website.


Biosimilars for Humira

A biosimilar is a medication that is highly similar to an existing FDA-approved biologic medicine (aka reference product). Biosimilars have the same strength, dosage, potential benefits, and side effects as the reference product and are administered the same way. Biosimilars still must be FDA-approved.

A woman doctor holds a clipboard and explains something to a patient.

Biologics and Biosimilars

Request your free resources to learn more about these two treatment options.

Request now
Illustrated graphic of people around a rocket ship and computer.

Tips and Tools

Weekly updates on living your best life with psoriatic disease.

Subscribe

Learn More About Your Treatment Options

The Patient Navigation Center is here to provide personalized information about your psoriasis and psoriatic arthritis treatment.

Contact a Patient Navigator today

Stay in the Know

Expert tips, can’t-miss events, and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logo

Copyright © 1996-2024 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication, or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.